Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Enterprise Value (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Enterprise Value for 6 consecutive years, with -$152.4 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 47.47% to -$152.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$152.4 million through Dec 2025, up 47.47% year-over-year, with the annual reading at -$152.4 million for FY2025, 47.47% up from the prior year.
  • Enterprise Value for Q4 2025 was -$152.4 million at TScan Therapeutics, up from -$184.5 million in the prior quarter.
  • The five-year high for Enterprise Value was -$95.6 million in Q1 2023, with the low at -$297.7 million in Q2 2024.
  • Average Enterprise Value over 5 years is -$181.8 million, with a median of -$172.5 million recorded in 2021.
  • The sharpest move saw Enterprise Value tumbled 363.93% in 2021, then soared 47.47% in 2025.
  • Over 5 years, Enterprise Value stood at -$161.4 million in 2021, then grew by 25.64% to -$120.0 million in 2022, then plummeted by 60.0% to -$192.0 million in 2023, then crashed by 51.06% to -$290.1 million in 2024, then skyrocketed by 47.47% to -$152.4 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$152.4 million, -$184.5 million, and -$218.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.